Výsledky vyhledávání - "Emmanuel Bey"

Akademický článek

Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1).

Autor: Alessandro Spadaro, Matthias Negri, Sandrine Marchais-Oberwinkler, Emmanuel Bey, Martin Frotscher

Publikováno v: PLoS ONE, Vol 7, Iss 1, p e29252 (2012)

17β-estradiol (E2), the most potent estrogen in humans, known to be involved in the development and progession of estrogen-dependent diseases (EDD) like breast cancer and endometriosis. 17β-HSD1, which catalyses the reduction of the weak estrogen e

Externí odkaz: https://doaj.org/article/8b5b42ff1bff47bcaee02bfde7a2d7c2

Zobrazit plný text záznamu

Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17β-HSD1 inhibitor with sub-nanomolar IC 50 for a proof-of-principle study

Autor: Emmanuel Bey, Chris J. van Koppen, Matthias W. Laschke, Mohamed Salah, Carsten Börger, Martin Frotscher, Ahmed S. Abdelsamie, Lorenz Siebenbürger, Michael D. Menger

Publikováno v: European Journal of Medicinal Chemistry. 127:944-957

Current endocrine therapeutics for the estrogen-dependent disease endometriosis often lead to considerable side-effects as they act by reducing estrogen action systemically. A more recent approach takes advantage of the fact that the weak estrogen es

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::681b60c43a98312f9761a0d03b45cfb3
https://doi.org/10.1016/j.ejmech.2016.11.004

Zobrazit plný text záznamu

Towards the evaluation in an animal disease model: Fluorinated 17β-HSD1 inhibitors showing strong activity towards both the human and the rat enzyme

Autor: Martin Frotscher, Ahmed S. Abdelsamie, Emanuele M. Gargano, Martin Empting, Emmanuel Bey, Chris J. van Koppen

Publikováno v: European Journal of Medicinal Chemistry. 103:56-68

17β-Estradiol (E2), the most potent human estrogen, is known to be involved in the etiology of estrogen-dependent diseases (EDD) like breast cancer and endometriosis. 17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) catalyses the last step of E2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cdc68e3a04485060a66e3174b7f570e
https://doi.org/10.1016/j.ejmech.2015.08.030

Zobrazit plný text záznamu

Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17β-HSD1 inhibitor with sub-nanomolar IC

Autor: Ahmed S, Abdelsamie, Chris J, van Koppen, Emmanuel, Bey, Mohamed, Salah, Carsten, Börger, Lorenz, Siebenbürger, Matthias W, Laschke, Michael D, Menger, Martin, Frotscher

Publikováno v: European journal of medicinal chemistry. 127

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e93f378196c8391163c5b644d1bd73c3
https://pubmed.ncbi.nlm.nih.gov/27852458

Zobrazit plný text záznamu

Novel estrone mimetics with high 17β-HSD1 inhibitory activity

Autor: Alexander Oster, Martin Frotscher, Matthias Negri, Sandrine Marchais-Oberwinkler, Patricia Kruchten, Emmanuel Bey, Tobias Klein, Rolf W. Hartmann, Ruth Werth

Publikováno v: Bioorganic & Medicinal Chemistry. 18:3494-3505

17Beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) catalyzes the reduction of estrone into estradiol, which is the most potent estrogen in humans. Lowering intracellular estradiol concentration by inhibition of this enzyme is a promising new op

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8c82a8c3cca429989e357ad007efd5b
https://doi.org/10.1016/j.bmc.2010.03.065

Zobrazit plný text záznamu

Development of biological assays for the identification of selective inhibitors of estradiol formation from estrone in rat liver preparations

Autor: Emmanuel Bey, Rolf W. Hartmann, Ruth Werth, Erika Ziegler, Martin Frotscher, Alexander Oster, Sandrine Marchais-Oberwinkler, Patricia Kruchten

Publikováno v: Comptes Rendus Chimie. 12:1110-1116

Estradiol (E2) is the most important estrogen in humans. Besides its physiological effects it is involved in the initiation and progression of estrogen dependent diseases like breast cancer and endometriosis. Common endocrine therapies have a strong

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ed0426a5ec033314572ebfd01138d3a1
https://doi.org/10.1016/j.crci.2009.05.005

Zobrazit plný text záznamu

Selective inhibition of 17β-hydroxysteroid dehydrogenase type 1 (17βHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells

Autor: Sandrine Marchais-Oberwinkler, Rolf W. Hartmann, Martin Frotscher, Emmanuel Bey, Alexander Oster, Ruth Werth, Patricia Kruchten

Publikováno v: The Journal of Steroid Biochemistry and Molecular Biology. 114:200-206

The most potent estrogen estradiol (E2) plays a pivotal role in the initiation and progression of estrogen dependent diseases. 17beta-Hydroxysteroid dehydrogenase type 1 (17betaHSD1) catalyses the NADPH-dependent E2-formation from estrone (E1). It is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ffc474cef49bd7329b3f26e8ba985ef
https://doi.org/10.1016/j.jsbmb.2009.02.006

Zobrazit plný text záznamu

The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17β-Hydroxysteroid Dehydrogenase (17β-HSD) type 1 and type 2

Autor: Rolf W. Hartmann, Ruth Werth, Sandrine Marchais-Oberwinkler, Martin Frotscher, Patricia Kruchten, Alexander Oster, Yaseen A. Al-Soud, Emmanuel Bey

Publikováno v: Molecular and Cellular Endocrinology
Molecular and Cellular Endocrinology, Elsevier, 2009, 301 (1-2), pp.212. ⟨10.1016/j.mce.2008.09.012⟩

17beta-Hydroxysteroid dehydrogenase type 1 (17beta-HSD1) is responsible for the catalytic reduction of the weak estrogen estrone (E1) into the highly potent 17beta-estradiol (E2). As 17beta-HSD1 is often overexpressed in mammary tumors and endometrio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ff4021139ee704dce9685ec37e47a37
https://doi.org/10.1016/j.mce.2008.09.012

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání